Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BeyondSpring stock

Own BeyondSpring stock in just a few minutes.

BeyondSpring Inc is a biotechnology business based in the US. BeyondSpring shares (BYSI) are listed on the NASDAQ and all prices are listed in US Dollars. BeyondSpring employs 61 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in BeyondSpring

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BYSI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BeyondSpring share price

Use our graph to track the performance of BYSI stocks over time.

BeyondSpring shares at a glance

Information last updated 2021-04-30.
52-week range$9.24 - $18.67
50-day moving average $10.93
200-day moving average $12.56
Wall St. target price$33.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.90

Buy BeyondSpring shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy BeyondSpring stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BeyondSpring financials

Gross profit TTM $0
Return on assets TTM -103.49%
Return on equity TTM -267.71%
Profit margin 0%
Book value $0.79
Market capitalisation $415.7 million

TTM: trailing 12 months

Shorting BeyondSpring shares

There are currently 1.2 million BeyondSpring shares held short by investors – that's known as BeyondSpring's "short interest". This figure is 0.3% down from 1.3 million last month.

There are a few different ways that this level of interest in shorting BeyondSpring shares can be evaluated.

BeyondSpring's "short interest ratio" (SIR)

BeyondSpring's "short interest ratio" (SIR) is the quantity of BeyondSpring shares currently shorted divided by the average quantity of BeyondSpring shares traded daily (recently around 211417.42808799). BeyondSpring's SIR currently stands at 5.91. In other words for every 100,000 BeyondSpring shares traded daily on the market, roughly 5910 shares are currently held short.

However BeyondSpring's short interest can also be evaluated against the total number of BeyondSpring shares, or, against the total number of tradable BeyondSpring shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BeyondSpring's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 BeyondSpring shares in existence, roughly 30 shares are currently held short) or 0.0452% of the tradable shares (for every 100,000 tradable BeyondSpring shares, roughly 45 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BeyondSpring.

Find out more about how you can short BeyondSpring stock.

BeyondSpring share dividends

We're not expecting BeyondSpring to pay a dividend over the next 12 months.

BeyondSpring share price volatility

Over the last 12 months, BeyondSpring's shares have ranged in value from as little as $9.24 up to $18.67. A popular way to gauge a stock's volatility is its "beta".

BYSI.US volatility(beta: 0.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BeyondSpring's is 0.5552. This would suggest that BeyondSpring's shares are less volatile than average (for this exchange).

BeyondSpring overview

BeyondSpring Inc. , a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site